Zobrazeno 1 - 10
of 263
pro vyhledávání: '"Bjørn Møller"'
Autor:
Raju Rimal, Trude E. Robsahm, Adele C. Green, Reza Ghiasvand, Corina S. Rueegg, Assia Bassarova, Petter Gjersvik, Elisabete Weiderpass, Odd O. Aalen, Bjørn Møller, Flavie Perrier, Marit B. Veierød
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Monitoring melanoma incidence time trends by tumour thickness is essential to understanding the evolution of melanoma occurrence and guiding prevention strategies. To assess long-term incidence trends, tumour thickness was extracted from pathology re
Externí odkaz:
https://doaj.org/article/bb069bd540eb421a9a48950034f9a3e4
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Lars Fjellbirkeland, Åslaug Helland, Bjørn Møller, Sissel Gyrid Freim Wahl, Steinar Solberg
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The main focus on the characteristics of malignant lung tumours has been the size, position within the lobe, and infiltration into neighbouring structures. The aim of this study was to investigate the distribution and characterist
Externí odkaz:
https://doaj.org/article/5875a883bc094aa79f00eb35ae725d73
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Morten Tandberg Eriksen, Marianne G. Guren, Erik Skaaheim Haug, Bjørn Naume, Ellen Schlichting, Bjørn Møller
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Cancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed to determine if 70% of cancer
Externí odkaz:
https://doaj.org/article/f1e88728779a43d0803e29d8f28fd44c
Autor:
Mark J. Rutherford, Therese M.-L. Andersson, Tor Åge Myklebust, Bjørn Møller, Paul C. Lambert
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Ensuring fair comparisons of cancer survival statistics across population groups requires careful consideration of differential competing mortality due to other causes, and adjusting for imbalances over groups in other prognostic
Externí odkaz:
https://doaj.org/article/c6e68e1605004a82942c98ab20276664
Publikováno v:
Norsk Epidemiologi, Vol 30, Iss 1-2 (2022)
Prostatakreft ble den dominerende kreftformen tidlig på 1960-tallet, mens brystkreft har vært den vanligste kreftformen blant kvinner siden Kreftregisteret ble etablert. I 2021 utgjorde prostata-, bryst-, tarm- og lungekreft, nesten halvparten (47%
Externí odkaz:
https://doaj.org/article/b5226dd6da0545f3b023b51cf0b7702c
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-18 (2021)
Abstract Background International differences in survival among colorectal cancer (CRC) patients may partly be explained by differences in emergency presentations (EP), waiting times and access to treatment. Methods CRC patients registered in 2015–
Externí odkaz:
https://doaj.org/article/a8abc6856f7b48569992236afb816fb8
Autor:
Kirsti Aas, Sophie Dorothea Fosså, Tor Åge Myklebust, Bjørn Møller, Rune Kvåle, Ljiljana Vlatkovic, Viktor Berge
Publikováno v:
Cancer Medicine, Vol 9, Iss 18, Pp 6646-6657 (2020)
Abstract Background The association between curative treatment (CurTrt) and mortality in senior adults (≥70 years) with high‐risk prostate cancer (PCa) is poorly documented. In a population‐based cohort we report temporal trends in treatment an
Externí odkaz:
https://doaj.org/article/3ff94467b2d24a6e9198588225327814
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Morten Tandberg Eriksen, Erik Skaaheim Haug, Bjørn Naume, Bjørn Møller
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Cancer patient pathways (CPPs) were implemented in 2015 to reduce waiting time, regional variation in waiting time, and to increase the predictability of cancer care for the patients. The aims of this study were to see if the nati
Externí odkaz:
https://doaj.org/article/2a3b37da840644dab4f585cacbab58d8
Autor:
Espen Enerly, Lena Holmstrøm, Anna Skog, Kristin Oterholt Knudsen, Jan F. Nygård, Bjørn Møller, Giske Ursin
Publikováno v:
Norsk Epidemiologi, Vol 29, Iss 1-2 (2021)
Until recently, there has been limited overview of the hospital administered cancer medications. The Cancer Registry of Norway has the approval to collect data on medical oncology treatment provided to each patient, but the reporting has so far been
Externí odkaz:
https://doaj.org/article/49043fbbe5bb415bb3e1b6edc6687f8c
Autor:
Øivind Kvammen, Tor Åge Myklebust, Arne Solberg, Bjørn Møller, Olbjørn Harald Klepp, Sophie Dorothea Fosså, Torgrim Tandstad
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0225942 (2019)
BackgroundTesticular germ cell tumor (TGCT) patients and survivors have excess mortality compared to the general male population, but relative survival (RS) has been scarcely studied. We investigated causes of excess mortality and their impact on RS
Externí odkaz:
https://doaj.org/article/ab48e52d2aee4d83bb547eb54b2dfbf4